TIMOTHY KASUNIC, MD

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Leuprolide acetate (for depot suspension), 7.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Biopsy and aspiration of bone marrow sample for diagnosis

New patient office or other outpatient visit, 45-59 minutes

Established patient office or other outpatient visit, 40-54 minutes

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 30-44 minutes

Established patient office or other outpatient visit, 30-39 minutes

Injection, rituximab, 10 mg

Injection, zoledronic acid, 1 mg

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Established patient office or other outpatient visit, 20-29 minutes

Telephone medical discussion with physician, 11-20 minutes

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of additional new drug or substance into vein, 1 hour or less

Administration of additional new drug or substance into vein using push technique

Infusion into a vein for hydration, 31-60 minutes

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Injection, pembrolizumab, 1 mg

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Administration of chemotherapy into vein, each additional hour

Injection, nivolumab, 1 mg

Injection of drug or substance under skin or into muscle

Irrigation of implanted venous access drug delivery device

Injection, carboplatin, 50 mg

Injection of additional new drug or substance into vein

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Injection, denosumab, 1 mg

Infusion into a vein for hydration, each additional hour

Injection, epoetin alfa, (for non-esrd use), 1000 units

Injection, leucovorin calcium, per 50 mg

Injection, methylprednisolone sodium succinate, up to 125 mg

Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg

Infusion, normal saline solution, sterile (500 ml = 1 unit)

Infusion, normal saline solution , 1000 cc

Injection, palonosetron hcl, 25 mcg

Injection, fluorouracil, 500 mg

Injection, aprepitant, 1 mg

Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

Injection, diphenhydramine hcl, up to 50 mg

Injection, magnesium sulfate, per 500 mg

Injection, ferric carboxymaltose, 1 mg

Injection, potassium chloride, per 2 meq

Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram

Injection, dexamethasone sodium phosphate, 1 mg